Body Systems

respiratory39 Results found

Studies recruiting participants:

Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs (SAPPHIRE)

The purpose of this study is to establish the efficacy and safety of repeated monthly dosing of endothelial progenitor cells (EPCs) transfected with human endothelial NO-synthase (eNOS) in patients with symptomatic severe pulmonary arterial hypertension (PAH) on available PAH-targeted medical the

Recruiting
Principal Investigator 
John Swiston
Body Locations and Systems 
Pulmonary Hypertension
Area 
Vancouver
Age 
18-80

GB001 in Adult Subjects With Moderate to Severe Asthma

The purpose of this study is to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.

Recruiting
Principal Investigator 
Mark FitzGerald
Body Locations and Systems 
Asthma
Area 
Vancouver
Age 
18-74

Tezepelumab COPD Exacerbation Study (COURSE)

The purpose of this study is to explore the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD).

Recruiting
Principal Investigator 
Mark FitzGerald
Body Locations and Systems 
COPD
Area 
Vancouver
Age 
40-80

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure.

Recruiting
Principal Investigator 
Kenneth Gin
Body Locations and Systems 
Heart Failure, Heart Attack
Area 
Vancouver
Age 
18 and above

International Lung Screen Trial (ILST)

People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer.

Recruiting
Principal Investigator 
Stephen Lam
Body Locations and Systems 
Lung Cancer
Area 
Vancouver
Age 
55-80

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 24 w

Recruiting
Principal Investigator 
John Swiston
Body Locations and Systems 
Pulmonary Hypertension
Area 
Vancouver
Age 
18-75

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delive

Recruiting
Principal Investigator 
Nasreen Khalil
Body Locations and Systems 
Pulmonary Fibrosis
Area 
Vancouver
Age 
40 years and above

Closed for recruitment:

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to…

The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD

Closed for Recruitment
Principal Investigator 
Jeremy D. Road
Body Locations and Systems 
COPD
Area 
Vancouver
Age 
40 and above

A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of…

The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum in patients experiencing an exacerbation of COPD, with or without tr

Closed for Recruitment
Principal Investigator 
Mark FitzGerald
Body Locations and Systems 
COPD
Area 
Vancouver
Age 
40-80

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial…

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arte

Closed for Recruitment
Principal Investigator 
John Swiston
Body Locations and Systems 
Pulmonary Hypertension
Area 
Vancouver
Age 
18-75

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe

Closed for Recruitment
Principal Investigator 
Mark FitzGerald
Body Locations and Systems 
Asthma
Area 
Vancouver
Age 
12 and above

Testing the efficacy and safety of a drug therapy in Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat alone or with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Closed for Recruitment
Principal Investigator 
Sasha Smiljanic
Body Locations and Systems 
Lung Cancer
Area 
Vancouver
Age 
18 and above